SC291 for B-Cell Malignancies

Recruiting at 9 trial locations

Overseen By Barbara Metallo

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Sana Biotechnology

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial tests SC291, a new drug for blood cancers, in patients with NHL or CLL who have tried multiple treatments. SC291 is given after chemotherapy to better target cancer cells.

Research Team

Cori Abikoff, MD

Principal Investigator

Sana Biotechnology, Inc.

Eligibility Criteria

This trial is for adults aged 18-75 with certain B-cell malignancies, including various types of non-Hodgkin's lymphoma and chronic leukemias. Participants must have relapsed or refractory disease after at least two prior treatments or a stem cell transplant, be relatively fit (ECOG status 0 or 1), and have a life expectancy of at least 12 weeks.

Inclusion Criteria

I have a type of large B-cell lymphoma.

I have been diagnosed with marginal zone lymphoma.

I have been diagnosed with CLL or SLL.

Treatment Details

Interventions

• SC291 (Other)

Trial Overview The study is testing SC291, an investigational drug for B-cell malignancies. It's in Phase 1 to assess safety, how well it works against cancer, its effects on the body over time, potential immune reactions to it, and any biomarkers that might predict who benefits from it.

Participant Groups

Group I: SC291 Plus Chemotherapy Regimen Experimental Treatment 1 Intervention

A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC291

Who Is Running the Clinical Trial?

Sana Biotechnology

Lead Sponsor

Trials

5

Recruited

12,100+